Literature DB >> 19253143

Risk stratification for invasive aspergillosis: early assessment of host susceptibility.

Thomas F Patterson1.   

Abstract

Outcomes of invasive aspergillosis are substantially improved with early initiation of therapy. Unfortunately, the diagnosis remains difficult to establish so that early suspicion of infection is imperative. Identification of high risk patients and use of non-culture-based diagnostics and radiographic studies can facilitate earlier recognition of infection. It is important to realize that the timing and spectrum of risk for invasive aspergillosis have expanded. While patients with hematological malignancies and hematopoietic stem cell transplants make up the highest risk groups, patients such as those receiving steroids and other immunosuppressive therapies are also at risk. Non-culture-based methods (including galactomannan, 1,3-beta-D-glucan, and PCR-based methods) are actively being pursued to improve early diagnosis. Thus, identifying patients at high risk for infection and utilizing non-culture-based methods and radiologic studies to assist in establishing a likely diagnosis of invasive aspergillosis will further enhance the role of new agents in the early, effective treatment and prophylaxis of invasive aspergillosis.

Entities:  

Mesh:

Year:  2009        PMID: 19253143     DOI: 10.1080/13693780902718339

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  10 in total

Review 1.  Diagnosis and treatment of invasive fungal infections in the cancer patient: recent progress and ongoing questions.

Authors:  Dimitrios P Kontoyiannis; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2014-11-15       Impact factor: 9.079

2.  Invasive fungal infections in acute leukemia.

Authors:  Vijaya R Bhatt; George M Viola; Alessandra Ferrajoli
Journal:  Ther Adv Hematol       Date:  2011-08

3.  Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Matthew W McCarthy; Laura L Kovanda; Myo H Zaw; Kaiser Hussain; Naima Shaikh; Bo Bo W Maung; Navjot K Sekhon; William W Hope; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

4.  Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis.

Authors:  M Hoenigl; J Prattes; B Spiess; J Wagner; F Prueller; R B Raggam; V Posch; W Duettmann; K Hoenigl; A Wölfler; C Koidl; W Buzina; M Reinwald; C R Thornton; R Krause; D Buchheidt
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

5.  Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Aspasia Katragkou; Bo Bo Win Maung; Ethan Naing; Povilas Kavaliauskas; Stephen Barat; Katyna Borroto-Esoda; Nkechi Azie; David Angulo; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

6.  Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients.

Authors:  Susanne Eigl; Juergen Prattes; Michaela Lackner; Birgit Willinger; Birgit Spiess; Mark Reinwald; Brigitte Selitsch; Michael Meilinger; Peter Neumeister; Frederike Reischies; Albert Wölfler; Reinhard B Raggam; Holger Flick; Stephan Eschertzhuber; Robert Krause; Dieter Buchheidt; Christopher R Thornton; Cornelia Lass-Flörl; Martin Hoenigl
Journal:  Crit Care       Date:  2015-04-17       Impact factor: 9.097

7.  Immunoproteome of Aspergillus fumigatus using sera of patients with invasive aspergillosis.

Authors:  Emylli D Virginio; Paula H Kubitschek-Barreira; Marjorie Vieira Batista; Marcelo R Schirmer; Eliana Abdelhay; Maria A Shikanai-Yasuda; Leila M Lopes-Bezerra
Journal:  Int J Mol Sci       Date:  2014-08-20       Impact factor: 5.923

8.  Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Patriss W Moradi; Gittel E Strauss; Aspasia Katragkou; Laura L Kovanda; William W Hope; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.938

Review 9.  Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome.

Authors:  Richard C Barton
Journal:  Scientifica (Cairo)       Date:  2013-01-14

10.  Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.

Authors:  Jon P Furuno; Gregory B Tallman; Brie N Noble; Joseph S Bubalo; Graeme N Forrest; James S Lewis; Ana F Bienvenida; Courtney A Holmes; Bo R Weber; Jessina C McGregor
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.